BMJ  2005;330 (19 February), doi:10.1136/bmj.330.7488.0-a

SSRIs and suicide: drug companies' trials are inconclusive

Data submitted by drug companies for a safety review by the Medicines and Healthcare Products Regulatory Agency don't lead to firm conclusions about a possible association between selective serotonin reuptake inhibitors (SSRIs) and suicide in adults. Gunnell and colleagues (p 385) systematically reviewed 477 randomised controlled trials comparing SSRIs with placebo in over 40 000 participants. They found only weak evidence of an increased risk of self harm among patients taking SSRIs when compared with placebo (odds ratio 1.57, 95% credible interval 0.99 to 2.55).

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Article

Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review

David Gunnell, Julia Saperia, and Deborah Ashby
BMJ 2005 330: 385. [Abstract] [Full Text] [PDF]